[{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","commit":"bfc8b4e2d8","date":"2026-09-10","author":"Jude Gomila","message":"Sources: BILCAP registry and publication links; official-website source on nineteen companies","file":"src/data/spikes/prostate.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.blueearthdiagnostics.com\" }]"}]},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/prostate.ts","type":"changed","fields":[{"field":"tldr","before":"\"Maker of Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.\"","after":"\"Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.\""},{"field":"summary","before":"\"Bracco subsidiary. Posluma approved 2023 (LIGHTHOUSE, SPOTLIGHT trials); rhPSMA therapeutic analogue in development.\"","after":"\"Blue Earth Diagnostics is a Bracco subsidiary. Posluma approved 2023 (LIGHTHOUSE, SPOTLIGHT trials); rhPSMA therapeutic analogue in development.\""}]}]